RxDoctor Payments Data

Annah Preszler, MD

Psychiatry · Bismarck, NDNPI 1710372362

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.4% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 25.7% of the total.

$609in general payments, 2019–2025

Across 26 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$157
  • Johnson & Johnson$102
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$75
  • E.r. Squibb & Sons, L.L.C.$53
  • Alkermes, Inc.$53
  • Axsome Therapeutics, Inc.$52
  • plus $118 from 4 others

What the payments were for

  • Food & beverage$55791%
  • Education$539%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$609 in reported general payments places this provider in the 75th percentile of 63 psychiatry providers in North Dakota.

See all psychiatry providers in North Dakota

Medicare billing

Part B allowed, 2024
$19,005
Medicare patients
28
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$91,545
VraylarCariprazine Hcl20$26,845
RexultiBrexpiprazole12$21,273
TrintellixVortioxetine Hydrobromide26$11,972
QuviviqDaridorexant Hcl11$5,558
Tranylcypromine Sulfate12$2,317
Quetiapine Fumarate100$1,139
Divalproex Sodium ErDivalproex Sodium46$1,104
Buspirone Hcl60$1,070
Duloxetine Hcl68$1,053
Bupropion XlBupropion Hcl28$818
Zolpidem Tartrate ErZolpidem Tartrate17$643
Escitalopram Oxalate85$584
Aripiprazole54$475
Sertraline Hcl63$469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$48$91,54511 claims
AbbVieVraylar$157$26,84520 claims
Otsuka America Pharmaceutical, Inc.Rexulti$22$21,27312 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$19$11,97226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 63 psychiatry providers in North Dakota.

Other psychiatry in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →